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Heart failure (HF) secondary to myocardial infarction (MI) remains a major source of morbidity and mortality, 
despite significant advances in therapies developed for this dis-
ease.1 The major determinant of survival after recovery from 
MI is left ventricular (LV) remodeling, which has been strongly 
associated with clinical outcomes in numerous HF trials.2
The cardiac renin–angiotensin–aldosterone system, which 
is highly activated after MI and in HF,3 has been implicated in 
the process of vascular and cardiac remodeling. Angiotensin II 
through its type 1 receptor (AT1R) induces myocardial hyper-
trophy, fibrosis, and cardiomyocyte apoptosis. Consequently, 
AT1R antagonists inhibit fibrosis in post-MI hearts.4 Both 
angiotensin-converting enzyme inhibitors and AT1R antago-
nists are cardioprotective with regard to post-MI LV dysfunc-
tion.4,5 Beneficial effects of AT1R blockade have at least, in 
part, been attributed to stimulation of unopposed angiotensin 
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type 2 receptors (AT2Rs), which counteract AT1R actions, thus 
promoting antigrowth, antiproliferation, and antifibrosis.6
AT2Rs are upregulated under experimental MI7 and in 
human heart with interstitial fibrosis,8 although in patients 
with HF, AT2R expression may be differently regulated.9 
Cardiac AT2R overexpression attenuates LV remodeling after 
MI in transgenic mice,10,11 whereas AT2R blockade impairs 
cardiac function after MI in rats.12 The recently developed 
nonpeptide AT2R agonist compound 21 (C21) allows direct, 
selective, and specific AT2R stimulation.13,14
We have recently demonstrated a profound improvement of 
cardiac function 7 days after MI by direct AT2R stimulation.15 
Beneficial effects were based on anti-inflammatory, antiapop-
totic, and antioxidative mechanisms. Importantly, C21 led to 
a significant attenuation of scar elongation after MI, pointing 
to a favorable effect of AT2R activation on post-MI cardiac 
remodeling.15 Furthermore, C21 prevented vascular remodel-
ing in L-NAME (NG-nitro-L-arginine methyl ester) hyperten-
sion16 and stroke-prone spontaneously hypertensive rats,17 and 
it preserved renal integrity by preventing inflammatory cell 
infiltration and collagen accumulation.18 However, it has not 
been investigated yet whether chronic AT2R stimulation has 
any effect on cardiac remodeling and resulting HF after MI.
The present study was designed to assess the long-term 
effects of treatment with the nonpeptide AT2R agonist C21 on 
cardiac function and structural myocardial alterations 6 weeks 
after MI. We studied the potential underlying mechanisms of 
AT2R activation on the heart by exploring extracellular matrix 
turnover processes of the postischemic myocardium, espe-
cially with regard to the tissue inhibitor of metalloprotease 1 
(TIMP1) and matrix metalloprotease 9 (MMP9) axis.
Methods
Animals
This study was performed in strict accordance with National and 
European guidelines for animal experiments with approval by the 
ethics commission of the regulatory authorities of the City of Berlin, 
Germany, the Landesamt fuer Gesundheit und Soziales (registration 
number G0307/06).
Experimental Protocol
MI was induced by ligation of proximal left anterior descending coro-
nary artery as previously described.15 Male Wistar rats were randomly 
assigned to the following groups: C21 treatment (0.03 mg/kg daily IP), 
vehicle treatment (0.9% NaCl), and sham-operated controls. Treatment 
was started 6 hours after MI. Animals with ejection fraction <35% 
were excluded from the experiment before assignment to groups. C21 
was kindly provided by Vicore Pharma (Gothenburg, Sweden).
Analysis of Hemodynamic Parameters
Transthoracic Doppler echocardiography (M-mode and Doppler 
measurements) was performed 1 and 6 weeks after MI in rats anesthe-
tized with isoflurane (2%) with the use of the high-resolution imaging 
system Vevo 770 (VisualSonics, Canada), and invasive hemodynamic 
assessment was performed at the end of the study using a fiber-optic 
pressure transducer catheter (Samba Sensors, Sweden) and Chart5 
software for analysis as previously described.15,19
Quantitative Real-Time Reverse Transcription 
Polymerase Chain Reaction, Western Blot Analysis, 
and ELISA
Quantitative real-time reverse transcription polymerase chain reac-
tion for measurement of MMP9, MMP2, and transforming growth 
factor β1 (TGF-β1) mRNA in heart tissues and TGF-β1 in cardiac 
fibroblasts (CFs) in vitro, as well as immunoblotting for MMP2, 
MMP9, TGF-β1, and TIMP1 protein expression in LV, was per-
formed according to standard protocols. TGF-β1 concentration in 
plasma was determined by ELISA. TGF-β1 expression in LV was 
studied immunohistochemically. Details of primers and antibodies 
can be found in the online-only Data Supplement.
Histology and Hydroxyproline Content  
in the Heart
Paraffin-embedded cross-sections of the heart were stained for 
collagen (sirius red/picric acid). Myocyte diameter was quantified 
by means of computer-aided histomorphometry by using of a ×40 
objective (×60 on monitor). The diameters were determined on a 
minimum of 30 myocytes from each animal (n=4) in noninfarcted 
regions. Interstitial fibrosis was quantified by means of computer-
aided histomorphometry (magnification ×60). Results were calcu-
lated as percentage of sirius red–positive areas in randomly chosen 
pictures from cardiac sections. The amount of collagen in the LV 
was analyzed by quantification of the tissue hydroxyproline content 
using the modified method based on alkaline hydrolysis as previ-
ously described.16,19
Cell Culture Experiments
Primary rat CFs were isolated as described by Agocha et al.20 CFs 
were incubated with interleukin 1α (IL-1α; 20 ng/mL, Sigma) in the 
presence or absence of C21 (0.25, 0.5, 1 μmol/L) and PD123319 (10 
μmol/L). MMP2 and MMP9 activity was analyzed by gelatin zymog-
raphy as described previously.21,22 mRNA expression of MMP9, 
MMP2, and TGF-β1 was evaluated by quantitative real-time reverse 
transcription polymerase chain reaction.
Fluorescence Microscopy
MMP9 and TIMP1 release was studied by fluorescence microscopy 
(Biorevo BZ-9000, Keyence Japan) in single CFs after stimulation 
with IL-1α (20 ng/mL) in the presence or absence of C21 (1 μmol/L) 
for 1, 4, 24, and 48 hours. Antibodies are specified in the online-only 
Data Supplement.
Statistical Analysis
Results are expressed as mean±SEM. Multiple comparisons were 
analyzed with 1-way ANOVA followed by the Bonferroni post hoc 
test. Two-group comparisons were analyzed by the 2-tailed Student 
unpaired t test for independent samples. Differences were considered 
statistically significant at a value of P<0.05.
Results
C21 Improves Systolic and Diastolic Cardiac 
Functions 6 Weeks After MI
Postinfarct mortality was 31%. Animal losses all occurred 
within the first 6 hours after MI before animals were assigned 
to the respective treatment groups.
Echocardiographic outcomes obtained 6 weeks after MI are 
presented in the Table. MI induced a significant LV dilation 
reflected by increased systolic LV inner diameter (P<0.05). 
Systolic function was impaired as evidenced by a decrease in 
LV ejection fraction (P<0.001), fractional shortening (P<0.01), 
and stroke volume (P<0.05). MI also deteriorated LV diastolic 
function, leading to an increase in the ratio of early (E) to late 
(A) ventricular filling velocities (E/A ratio; P<0.05) and short-
ening of E-wave deceleration time (P<0.01; Table).
Chronic treatment with C21 significantly improved systolic 
function, raising ejection fraction by 17.8% (P<0.001) and 
fractional shortening by 9.9% (P<0.05) versus vehicle. C21 
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also reduced systolic LV inner diameter from 5.2±0.7 mm in 
vehicle-treated to 4.4±0.4 mm (P<0.05) in C21-treated rats 
and diastolic LV inner diameter from 8.7±0.6 to 7.8±0.5 mm 
(P<0.05), respectively. C21 further improved cardiac wall 
motion (Figure S1A in the online-only Data Supplement). 
Improvement of diastolic function by C21 was evidenced by 
a 17.4% decrease in E/A ratio (P<0.05; versus vehicle; Table; 
Figure S1B).
Hemodynamic parameters measured via intracardiac 
Samba catheter are presented in Figure 1. Rats with MI devel-
oped systolic dysfunction, as evidenced by decreased contrac-
tility index (125.4±4.2 versus sham 142.3±2.0 L/s; P<0.05; 
Figure 1A) and maximal peak rate of LV pressure increase 
(dP/dt
max
: 9364±369 versus sham 11 959±420 mm Hg/s; 
P<0.05; Figure 1B).
Rats with MI also exhibited a severe diastolic dysfunc-
tion, as defined by elevated LV end-diastolic pressure 
(22.1±1.4 versus sham 14.4±1.0 mm Hg; P<0.05; Figure 2D), 
increased minimal peak rate of LV pressure increase (dP/dt
min; 
–10 262±464 versus sham –12 524±529 mm Hg/s; P<0.05; 
Figure 1E), and reduced diastolic duration time (P<0.01; 
Figure 1F).
C21 significantly improved systolic cardiac function, 
enhancing contractility index (141.7±4.2 versus vehicle 
125.4±4.2 L/s; P<0.05) and dP/dt
max
 (11 540±594 mm Hg/s 
versus 9364±369 mm Hg/s; P<0.05; Figure 1A and 1B) and 
reducing LV maximal pressure (P<0.05; Figure 1C).
C21 demonstrated favorable effects on the diastolic func-
tion by reducing LV end-diastolic pressure (16.9±1.2 versus 
vehicle 22.1±1.4 mm Hg; P<0.05) and dP/dt
min (–11 805±398 
versus vehicle –10 262±464 mm Hg/s; P<0.05; Figure 1D 
and 1E) and by increasing diastolic duration time (P<0.05; 
Figure 1F).
To assess indirect parameters of arterial stiffness, pulse wave 
analysis was performed on pressure curves obtained from the 
ascending aorta. The augmentation index in vehicle-treated 
animals was increased (25.4±1.2 versus sham 15.57±1.3; 
P<0.05), and C21 attenuated this increase (17.8±1.2 versus 
vehicle 25.4±1.2; P<0.05).
Myocyte Diameter, Collagen Content, and 
Expression of TGF-β1 in the Heart 6 Weeks  
After MI
Myocyte diameter was significantly increased 6 weeks 
 post-MI (12.57±1.85 versus sham 10.56±1.50 μm; P<0.01), 
and C21 treatment further increased the diameter of myo-
cytes (15.38±1.30 versus vehicle 12.57±1.85 μm; P<0.001; 
Figure S2).
Less collagen accumulation was found in the heart after 
C21 treatment as demonstrated by staining with the collagen- 
specific dye sirius red (Figure S3). Interstitial fibrosis was 
markedly increased in the noninfarcted region of vehicle- 
treated post-MI animals (5.5±0.3% versus sham 2.8±0.3%; 
P<0.01); treatment with C21 completely prevented this effect 
(3.0±0.2% versus vehicle 5.5±0.3%; P<0.001; Figure S4A).
Collagen content was studied by measuring tissue hydroxy-
proline concentration. Hydroxyproline increased by 24% 
(P<0.01) post-MI compared with sham group, whereas C21 
attenuated this increase (P<0.05; Figure S4B).
Because fibrosis is promoted by TGF-β1, its expression 
was investigated in the peri-infarcted zone. In the vehicle 
group, TGF-β1 was strongly enhanced in fibrotic tissues and 
cardiomyocytes (Figure 2A). C21 prevented the overexpres-
sion of TGF-β1.
Accordingly, TGF-β1 expression in the LV, which was 
significantly upregulated both on the mRNA (1.3-fold; 
P<0.05) and particularly on protein levels (40-fold; P<0.01) 
post-MI, was completely abolished by C21 (P<0.01; Figure 
2B and 2C).
Furthermore, serum concentration of active TGF-β1 tended 
to be elevated 6 weeks post-MI, whereas the latent form of 
TGF-β1 was decreased (P<0.05; Figure 2D and 2E). C21 
treatment normalized the levels of both forms (P<0.05).
Regulation of TIMP1, MMP2, and MMP9 by C21 
in the LV 6 Weeks After MI
As demonstrated in Figure 3A and 3B, MMP9 was upregu-
lated post-MI both at the mRNA (2.9-fold; P<0.05) and pro-
tein levels (3.6-fold; P<0.001). C21 treatment significantly 
attenuated this increase.
MMP2 protein but not mRNA was also upregulated 
(Figure S5). Zymographic analysis of the LV post-MI 
extracts demonstrated an increased release of active MMP9 
(Figure 3C and 3D). Again, C21 significantly prevented 
MMP9 secretion, whereas there was no statistically signifi-
cant effect on MMP2 activity (Figure 3E). Protein expression 
of TIMP1, the native inhibitor of MMP9, was lower after MI 
(Figure 3F). C21 strongly reversed this decrease (17.7-fold; 
P<0.01) and, in turn, attenuated the increased MMP9/TIMP1 
ratio (Figure 3G).
Regulation of TIMP1, MMP2, MMP9, and TGF-β1 
Expression in Rat Primary CFs
Zymographic analysis of MMP9 and MMP2 activity in CFs 
is presented in Figure 4. C21 prevented the IL-1α–stimulated 
secretion of MMP9 in a concentration-dependent manner, 
whereas MMP2 release was not influenced. AT2R blockade 
with PD123319 thoroughly abolished the effect of C21 on the 
Table.  Hemodynamic Variables in Wistar Rats Measured 6 
Weeks After MI by Transthoracic Doppler Echocardiography
Hemodynamic 
Parameter Sham Vehicle
C 21
0.03 mg/kg per day
EF, % 74.6±2.51 53.4±7.03* 71.2±4.74†
FS, % 50.5±5.19 30.9±3.08‡ 40.8±2.32§
LVIDd, mm 7.9±0.14 8.7±0.63 7.8±0.54§
LVIDs, mm 4.7±0.47 5.2±0.76║ 4.4±0.48§
E/A 1.8±0.17 2.3±0.13║ 1.9±0.09§
EDT, ms 17.8±2.29 12.4±0.78‡ 15.6±1.61
Stroke volume, μL 44.3±5.37 35.6±1.42║ 39.4±2.95
Heart rate, bpm 339.3±11.84 357.8±6.46 335.3±6.29
E/A indicates ratio between early (E) and late (atrial [A]) ventricular filling 
velocity; EDT, deceleration time of early filling wave; EF, ejection fraction; FS, 
fractional shortening; LVIDd, diastolic left ventricular inner diameter; LVIDs, 
systolic left ventricular inner diameter; and MI, myocardial infarction.
*P<0.001 vs sham; †P<0.001 vs vehicle; ‡P<0.01; §P<0.05; ║P<0.05.
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IL-1α–induced MMP9 secretion (Figure S6). C21 also signifi-
cantly attenuated TGF-β1 mRNA upregulation (Figure S7).
The results of TIMP1 and MMP9 immunostaining in 
CFs are presented in Figure 5. After stimulation with IL-1α, 
MMP9 (red stain) was expressed in cytoplasm already at 4 
hours and reached its maximum at 48 hours. TIMP1 (green 
stain) appeared 24 hours after stimulation, was colocalized 
(yellow stain) with MMP9, and disappeared at 48 hours. In 
C21-treated cells, TIMP1 was strongly expressed already 4 
hours after IL-1α stimulation, reached maximum at 24 hours, 
and was distinguishable until 48 hours in a colocalization with 
MMP9. In C21-treated cells, even at 48 hours after stimula-
tion not linked MMP9 (red stain) was undistinguishable.
Discussion
This study describes protective effects of long-term selec-
tive AT2R stimulation with the AT2R agonist C21 in a chronic 
model of MI. C21 improved both systolic and diastolic heart 
functions, largely prevented post-MI LV dysfunction, and 
reduced arterial stiffness.
The present study is in line with our previous data obtained 
7 days after MI, which showed an improvement of cardiac 
function in the acute phase after MI. In this earlier study, 
the favorable effect of AT2R stimulation with C21 on cardiac 
function was prevented by the AT2R antagonist, PD123319, 
confirming AT2R specificity of C21 actions.15 Hemodynamic 
data are also in agreement with recent investigations per-
formed in an AT2R overexpression model, where the AT2R 
protected the heart from ischemic injury 4 weeks post-MI.23 
However, in a study looking at cardiac function and remodel-
ing in a model of MI induced by coronary occlusion–reper-
fusion in mice, no attenuation of post-MI LV remodeling by 
a 4-week treatment with C21 was observed.24 The lack of 
treatment effect of C21 in this study was probably because 
of the application of the same dose of C21 that is usually 
used for bolus injections (0.3 mg/kg bw) by minipump for 
24 hours, which considering a plasma half-life of C21 of 
maximum 4 hours results in too low plasma levels and thus 
in underdosing.
In the late phase post-MI, adverse postischemic cardiac 
remodeling is characterized by fibrotic processes and col-
lagen deposition in the remote myocardium, which have the 
potential of increasing LV mass at the cost of LV function.25 
Therefore, the role of AT2R stimulation in post-MI cardiac 
Figure 1. Hemodynamic parameters measured in 
left ventricle (LV) by intracardiac Samba catheter 6 
weeks after myocardial infarction. A, Contractility 
index. B, Maximal peak rate of LV pressure 
increase (microvascular permeability index, dP/
dtmax). C, LV maximal pressure. D, LV end-diastolic 
pressure. E, Minimal peak rate of LV pressure 
increase (dP/dtmin). F, Diastolic duration; **P<0.01, 
*P<0.05 vs sham; †P<0.05 vs vehicle; (n=8 in each 
group, mean±SEM); 1-way ANOVA.
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fibrosis and the underlying mechanisms were the focus of 
this study.
We found that C21 decreased interstitial fibrosis and col-
lagen accumulation in the remote myocardium after ischemia. 
In parallel, C21 reduced the increased augmentation index, 
which characterizes arterial stiffness and correlates with vas-
cular fibrosis, as well as with the severity of LV hypertrophy 
and coronary heart disease.26 These data are in agreement with 
previous reports demonstrating an antifibrotic effect of the 
AT2R agonist in the aorta of L-NAME–treated hypertensive 
rats16 and in the vessels and heart of SHR.17
Interestingly, C21 administration reinforced post-MI compen-
satory hypertrophy of cardiac myocytes and by this mechanism 
possibly contributed to functional improvement of the heart.
A similar trend was seen by Voros et al,27 but in their study 
did not reach statistical significance probably because of lim-
ited power of the study as the authors state in the discussion.
We further investigated the effect of AT2R stimulation on 
TGF-β1 expression, a profibrotic cytokine that is extensively 
expressed after ischemia and is upregulated by angiotensin II 
via AT1R activation in cardiac myocytes and fibroblasts.28,29 
This study is the first to demonstrate that AT2R stimulation 
prevents the increase in TGF-β1 expression after MI, both at 
protein and transcriptional levels. The elevated serum concen-
tration of active TGF-β1 was also decreased by C21. In vitro 
experiments in primary CFs further demonstrated that C21 
attenuated the IL-1α–induced increase in TGF-β1 mRNA 
expression, suggesting its regulation through a direct effect 
of AT2R stimulation on the regulation of TGF-β1 expression.
The degradation of matrix components by MMPs and the 
resulting side-by-side slippage of cardiomyocytes are other 
mechanisms that may contribute to LV wall thinning in the 
remote region after MI.25 It is, therefore, suggested that the 
interplay of MMPs and their regulators is important in the 
development of myocardial fibrosis and post-MI LV dysfunc-
tion and that HF can be modified by modulating MMP activity.
Gelatinases MMP2 and MMP9 have been shown to be main 
regulators of ECM (extracellular matrix) in cardiac tissue 
because they possess substrate affinity for denatured fibrillar 
collagen and exhibit proteolytic activity against elastin and 
proteoglycans.30
MI induced the proteolytic activity of MMP9 in the LV, 
which was attenuated by C21 treatment. Similarly, C21 dose 
dependently decreased gelatinolytic activity of MMP9 in CFs. 
Furthermore, C21 regulated the expression of TIMP1, the 
natural inhibitor of MMP9. Deficiency of TIMP1 is known to 
promote LV dilatation and increase LV end-diastolic volume31 
and has also been demonstrated to exacerbate LV remodeling 
after MI in mice after MI.32
In our study, the higher concentration of MMP9 and the 
increased MMP9/TIMP1 protein expression ratio in cardiac 
tissue post-MI evidenced the proteolytic dysbalance, which 
was ameliorated by treatment with C21. The molecular mech-
anisms, by which the AT2R inhibits proteolysis, are complex 
and require further investigation, but several possible interac-
tions exist.
First, the AT2R seems to be involved in the interplay between 
MMPs and TGF-β1. Increasing evidence points toward the 
Figure 2. Transforming growth factor (TGF) β1 
expression in left ventricle (LV) 6 weeks after 
myocardial infarction. A, Immunostaining of  TGF-
β1, red stain, ×40. B, Western blot analysis of  TGF-
β1. Densitometric data of proteins are mean±SEM 
(n=6). C, Relative expression of TGF-β1 mRNA 
in LV (n=6). D, Concentration of latent TGF-β1 in 
serum (n=6). E, Concentration of active TGF-β1 in 
serum (n=6); **P<0.01, *P<0.05 vs sham; ††P<0.01, 
†P<0.05 vs vehicle; 1-way ANOVA.
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possibility that TGF-β1 increases MMP activity within the 
myocardium.29 However, MMP9 and MMP2 are both able to 
cleave latent TGF-β1, releasing its active form,33 which in turn 
activates transcription of TIMPs.34 This suggests that a feed-
forward loop could develop in cardiac remodeling, in which 
the roles of MMPs and TGF-β1 are intertwined.
Figure 4. Effect of compound 21 (C21) on 
cytokine-induced matrix metalloproteinase 9 
(MMP9) and MMP2 secretion in cardiac fibroblasts 
(CFs). Activity of MMP9 (A) and MMP2 (B) in CFs 
determined via gelatin zymography. Bars represent 
densitometric data of 3 independent experiments 
(mean±SEM). C, Representative gelatin zymogram 
loaded with conditioned media from CFs. 
***P<0.001 vs sham; ††P<0.01, †P<0.05 vs vehicle; 
1-way ANOVA.
Figure 3. Matrix metalloproteinase 9 (MMP9; A) 
and tissue inhibitor of matrix metalloproteinase 
1 (TIMP1; F) protein expression and MMP9/
TIMP1 ratio (G) in left ventricle 6 weeks after 
myocardial infarction. Representative images and 
densitometric data of proteins are mean±SEM 
(n=6). B, MMP9 mRNA. C, Representative gelatin 
zymogram loaded with heart tissue extracts. 
Semiquantitative analysis of MMP9 (D) and MMP2 
(E) activity in heart tissues measured by gelatin 
zymography (n=3). **P<0.01, *P<0.05 vs sham; 
††P<0.01, †P<0.05 vs vehicle; 1-way ANOVA.
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TIMP1 activation may contribute to antiproteolytic effects 
of C21 in the heart. Our immunostaining experiments per-
formed in single CFs and determining the time course of 
AT2R-induced expression of TIMP1 and MMP9 suggest that 
C21 in a first step activates TIMP1 followed by inhibition of 
MMP9. TIMP1 is also known to possess antiapoptotic activ-
ity,35 and this fact is in accordance with antiapoptotic proper-
ties of C21 demonstrated previously.15,36 Thus, TIMP1 may be 
a major mediator of the cardioprotective effects of C21. Given 
that MMPs generally play a pivotal role in extracellular matrix 
degradation, the antiproteolytic effect of C21 might be of 
great relevance for tissue remodeling in various pathologies.
It is a limitation of this study that we did not have an animal 
group treated with C21 plus an AT2R antagonist (PD123319) 
to prove AT2R specificity of the observed protective effects of 
C21. However, AT2R specificity of a beneficial effect of C21 
on post-MI cardiac performance has been shown by us in a 
previous study with shorter duration.15 Furthermore, we dem-
onstrate in this study in in vitro experiments that the inhibitory 
effect of C21 on MMP activity, which is an entirely new find-
ing, is AT2R specific, that is, reversible by PD123319.
Perspectives
This study demonstrates that long-term stimulation of the 
AT2R with C21 improved postischemic cardiac function by 
preventing adverse myocardial remodeling and reducing 
proteolysis. Furthermore, C21 activated TIMP1, inhibited 
MMP9, and decreased TGF-β1 expression as well as collagen 
accumulation in the heart.
This study is of clinical relevance because it supports the 
hypothesis that AT2R stimulation could represent a novel thera-
peutic concept in postischemic LV remodeling and HF treatment.
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What Is New?
•	Angiotensin type 2 receptor (AT2R) stimulation by the selective nonpep-
tide agonist compound 21 improved systolic and diastolic functions in 
the late stage post–myocardial infarction in rats.
•	AT2R stimulation prevented fibrosis of peri-infarct myocardium and im-
proved arterial stiffness parameters.
•	The main cellular mechanisms underlying cardiac protection by AT2R 
stimulation include antiproteolysis via the activation of tissue inhibitor 
of matrix metalloproteinase 1 and inhibition of matrix metalloproteinase 
9, as well as antifibrosis via decreased transforming growth factor β1 
expression in the heart.
What Is Relevant?
•	AT2R stimulation by compound 21 improves cardiac function in the 
late stage post–myocardial infarction and ameliorates left ventricular 
remodeling.
Summary
AT
2
R stimulation could represent a novel therapeutic concept in 
postischemic left ventricular remodeling and heart failure treatment.
Novelty and Significance
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Expanded Materials and Methods 
 
Animals 
Male normotensive Wistar rats (weight 200 to 220g; Harlan Winkelmann, Borchen, Germany) 
were kept in a specific pathogen-free barrier under standardized conditions with respect to 
temperature (23±1°C) and humidity and were housed on a 12-hour light/dark cycle in groups 
of 5 animals with food and water ad libitum. 
 
Myocardial infarction 
Under anaesthesia with ketamine/xylazine (80/10 mg/kg i.p.) rats were intubated and 
connected with a small-animal ventilator with room air at a rate of 75 cycles/min and 3.5mL 
tidal volume. Left lateral thoracotomy was performed, and a suture was tightened around the 
proximal left anterior descending coronary artery. Sham-operated rats underwent the same 
surgical procedure with the exception of the coronary ligature. Analgesic Flunixin-Meglumine 
(1,0 mg/kg i.p.) was applied 45 min before anesthesia and daily 3 days after operation.  
The number of animals per group was 12 in C21 and vehicle treated and 8 in sham operated 
groups at the time of euthanasia. C21 was dissolved in 0,9%NaCl and administered 
0,03mg/kg daily i.p. 
 
Western Blot Analysis 
Protein lysates were prepared according to standard protocols. Protein expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Immunoreactive bands 
were detected by enhanced chemiluminescence (GE Health Care, Germany) and quantified 
with ImageJ software. 
 
 
Antibodies for Western Blot analysis 
Antibodies Source Dilution  Manufacturer 
Primary 
antibodies 
MMP-2 Polyclonal rabbit 1:1000  Abcam  
MMP-9 Polyclonal rabbit 1:1000  Abcam 
TIMP-1 Polyclonal rabbit 1:500 Santa Cruz 
TGF-β Polyclonal rabbit 1:500 Santa Cruz 
GAPDH Monoclonal mouse 1:500 MerckMillipor 
Secondary 
antibodies 
Anti-mouse Polyclonal goat 1:2000 Dako 
Anti-rabbit Polyclonal goat 1:2000 Dako 
 
 
Antibodies for fluorescence microscopy  
Antibodies Source Dilution Manufacturer 
 
MMP-2 Polyclonal mouse 1:200 Santa Cruz 
MMP-9 Polyclonal mouse 1:200 Santa Cruz 
TIMP-1 Polyclonal rabbit 1:200 Santa Cruz 
TGF-β Polyclonal rabbit 1:200 Santa Cruz 
Secondary 
antibodies 
anti-mouse Cys3 Polyclonal mouse 1:250 Dianova 
anti-mouse FITC Polyclonal rabbit 1:250 Dianova 
anti-rabbit Polyclonal goat 1:200 DAKO 
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LVIDd LVIDs 
Immunohistochemistry  
Immunohistochemistry of TGF-β1 was performed in paraffin-embedded tissue sections (5µm) 
using the avidin-biotin complex method according to the manufacture's instructions 
(Vectastain ABC; Vector Laboratories, Burlingame, California, USA). Peroxidase activity 
was visualized by 3-amino-9-ethylcarbazole (AEC, Vector Laboratories). Primary antibodies 
against TGF-β1 (1:50, Santa Cruz Biotechnology Inc., Heidelberg, Germany) were used.   
 
mRNA analysis 
Total RNA from LV tissue and CFs was isolated by TRIZOL reagent (Invitrogen) and 
subsequently treated with DNase-I (Promega). qRT-PCR was performed with MX3005p 
QPCR System (Stratagene) using SYBR green reaction mix and primers indicated in 
supplement. All samples were measured in triplicate, and expression values were normalized 
to 18s rRNA. Data analysis was done using the MxPro™ ET QPCR software (Stratagene) and 
∆∆Ct-method.  
 
Primers 
Gene (Rat) Primer sequences for SYBR Green® real-time PCR 
18s Forward: 5’- GGGAGGTAGTGACGAAAAATAACAAT-3’  Reverse:  5’- TTGCCCTCCAATGGATCCT-3’ 
MMP 2 Forward: 5’- GACGCTGGGAGCATGGAG-3’  Reverse:  5’- TTACGCGGACCACTTGTCC-3’ 
MMP 9 Forward: 5’- CTTCTCTGGGCGCAAAATG-3’  Reverse:  5’- CCGGTGACCAGGGTTACCT-3’ 
TIMP1 Forward: 5’- TCTGGCATCCTCTTGTTGCT-3’ Reverse:  5’- CACAGCCAGCACTATAGGTCTTT-3’ 
TGF-β1 Forward: 5’- GGTGGACCGCAACAACGCAATCTA-3’   Reverse: 5’- GGGTGGCCATGAGGAGCAGGAA-3’ 
 
Figures 
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Figure S1. Effect of the C21 treatment on cardiac function 6 weeks post-MI. (A): M-mode 
echocardiograms of LV. Note LV dilatation, thinning and akinesis of the anterior wall in 
vehicle-treated rats. Diastolic (LVIDd) and systolic (LVIDs) inner dimensions are increased 
compared with sham-operated animals. C21 prevented LV dilation and improved anterior 
wall motion.  
(B): Pulsed-wave Doppler spectra of mitral inflow. Note an augmentation of E-wave (early 
diastolic filling velocity), reduction of A-wave (atrial contraction filling velocity) in vehicle-
treated rats vs. healthy rats. C21 reversed MI-induced alterations in E and A-waves almost 
back to sham level.  
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Figure S2: Myocyte diameter was quantified in cardiac sections by means of computer-aided 
histomorphometry, magnification x60. All of the values are given as mean±SEM; **p<0.01 
versus sham group; †††p< 0.001 versus vehicle; one-way ANOVA. 
 
 
 
 
 
 
 
 
Figure S3: Representative cross-sections from LV 6 weeks after MI. Sirius red stain. 
Collagen fibers are stained red and cardiac myocytes are yellow, 40x. Note diffuse interstitial 
fibrosis in vehicle-treated animals which is partly prevented by C21 treatment. 
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Figure S4: (A) Intersitial fibrosis was quantified in Sirius Red-stained cardiac sections by 
means of computer-aided histomorphomentry, magnification x200. Results were calculated as 
percentage of Sirius-Red-positive area in randomly chosen pictures from cardiac sections.  
(B) Hydroxyproline concentration in septum 6 weeks after MI (n=3); All of the values are 
given as mean±SEM; ***p<0.001, **p<0.01 versus sham group; †††p< 0.001, †p<0.05 
versus vehicle; one-way ANOVA. 
 
 
 
 
Figure S5: (A) MMP2 expression measured in LV 6 weeks post-MI. Western blot analysis 
(n=6). Representative image and densitometric data of proteins are mean ± SEM; (B): MMP2 
mRNA. **p<0.01, *p<0.05 versus sham; †p<0.05 versus vehicle; one-way ANOVA. 
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Figure S6. Effect of C21 and combination of C21 (1µM) plus PD 123319 (10µM) on 
cytokine-induced MMP9 and MMP2 secretion in CFs. Activity of MMP9 and MMP2 in CFs 
determined via gelatine zymography. PD 123319 abolished the effect of C21 on the IL-1 
alpha induced MMP9 secretion. 
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Figure S7. TGF-β1 mRNA expression measured in primary rat cardiac fibroblasts. Bars 
represent densitometric data of three independent experiments (mean ±S.E.M). C21 reduces 
IL 1α-stimulated release of TGF-β1 by cardiac fibroblasts. **p<0.01 versus sham; ††p<0.01, 
†p<0.05 versus vehicle; one-way ANOVA. 
 
IL-1α           -              +               +              +        
C21                 -                 -              +          + 
PD123319         -           -              -                + 
